Multi-institutional phase 2 study of TLK286 (TELCYTAtm, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Mannervik B, 1988, CRC Crit Rev Biochem, 23, 283, 10.3109/10409238809088226

Green JA, 1993, Br J Cancer, 68, 235, 10.1038/bjc.1993.321

Toffoli GAV, 1992, Eur J Cancer, 28, 1441, 10.1016/0959-8049(92)90540-I

Montali JA, 1995, Cell Pharmacol, 2, 241

10.1016/S0304-3835(96)04471-0

Kase H, 1998, Acta Cytol, 42, 1397, 10.1159/000332174

Lyttle MH, 1994, J Med Chem, 37, 1501, 10.1021/jm00036a016

Satyam A, 1996, J Med Chem, 39, 1736, 10.1021/jm950005k

Meng F, 2001, Proc AACR-NCI-EORTC, 67, 327

Xu H, 2004, Proc AACR, 559

Izbicka E, 1997, Anticancer Drugs, 8, 345, 10.1097/00001813-199704000-00006

Morgan AS, 1998, Cancer Res, 58, 2568

Rosario LA, 2000, Proc 11th NCI-EORTC-AACR Symp, 66, 114

Rosen LS, 2003, Clin Cancer Res, 9, 1628

Rosen LS, 2004, Clin Cancer Res, 10, 3689, 10.1158/1078-0432.CCR-03-0687

10.1093/jnci/92.3.205

Fleming TR, 1982, Biometrics, 38, 143, 10.2307/2530297

Ozols R, 1997, Cancer: principles and practice of oncology, 5, 1514

Markman M, 2004, Oncologist, 5, 26, 10.1634/theoncologist.5-1-26

Markman M, 2004, Gynecol Oncol, 93, 699, 10.1016/j.ygyno.2004.03.023

Cesano A, 1999, Int J Oncol, 15, 1233

Gordon AN, 2001, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312

Xu H, 2004, Proc of AACR, 2008

Kavanagh JJ, 2004, Proc Am Soc Clin Oncol, 5060, 462

Brown GL, 2004, Proc Am Soc Clin Oncol, 5062, 463

Papadimitrakopoulou V, 2004, Proc Am Soc Clin Oncol, 7140, 648